Skip to Content

Enfortumab vedotin sets new standard for 3rd line treatment of advanced bladder cancer

The antibody drug-conjugate enfortumab vedotin significantly prolongs survival compared to standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top